Compounded Pain Cream: A Formulation Guide for Prescribers

Short answer: A compounded pain cream is a non-sterile topical preparation that places one or more analgesic or anaesthetic actives — such as ketamine, amitriptyline, gabapentin, lidocaine or an NSAID — directly at the site of pain, minimising systemic exposure compared with oral therapy. The evidence base for topical analgesics is strongest for NSAIDs in musculoskeletal pain and for specific actives such as capsaicin and lidocaine in neuropathic conditions, while the evidence for multi-active compounded combinations is more limited and heterogeneous. Formulation decisions — base selection, active concentration, excipient compatibility and stability — determine whether the active reaches its target, and every preparation is made for a named patient on a doctor’s prescription under Good Compounding Practice (GCP).

Clinical indications appropriate for topical analgesia

Topical analgesia is considered when the pain source is accessible to transdermal or trans-mucosal delivery and systemic side effects from oral therapy are a concern. The clinical settings where topical analgesics have been studied include localised musculoskeletal pain, neuropathic pain (post-herpetic neuralgia, diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy) and focal inflammatory pain.

A Cochrane systematic review of topical NSAIDs for acute musculoskeletal pain found that topical NSAIDs were effective for acute strains, sprains and overuse injuries, with a number needed to treat of approximately 4.7 for at least 50% pain relief over 7–14 days (Derry et al., Cochrane Database of Systematic Reviews, 2015. PMID 26068955). A separate Cochrane review for chronic musculoskeletal pain reported similar efficacy, though the evidence quality was lower in chronic settings (Derry et al., Cochrane Database of Systematic Reviews, 2016. PMID 27103611).

For neuropathic pain, a Cochrane overview of topical analgesics summarised the evidence across multiple actives and concluded that topical NSAIDs, capsaicin and lidocaine each have a place, while the evidence for many compounded combinations remains limited (Derry et al., Cochrane Database of Systematic Reviews, 2017. PMID 28497473). A Cochrane review of topical lidocaine for neuropathic pain noted that while widely used in clinical practice, the quantity and quality of evidence was insufficient to support a strong recommendation, reflecting the reality that many compounded topical analgesics are prescribed on mechanistic rationale rather than large-scale trial data (Derry et al., Cochrane Database of Systematic Reviews, 2014. PMID 25058164).

Formulation options — base choices and concentrations

The vehicle is not an inert carrier; it governs how much active is released, how far it penetrates and how well it is tolerated. Common bases for compounded pain creams include pluronic lecithin organogel (PLO), which enhances penetration of lipophilic actives, and anhydrous or aqueous cream bases selected for compatibility with the specific active.

Typical active concentrations reported in the compounding literature and clinical studies include:

• Ketamine — 1% to 10%, an NMDA receptor antagonist. A randomised, double-blind, placebo-controlled trial of topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes did not demonstrate significant benefit over placebo, highlighting that low concentrations may be insufficient for some patients (Lynch et al., Anesthesiology, 2005. PMID 15983466). An open-label trial of topical ketamine 10% in spinal cord injury patients reported pain reduction, suggesting concentration may matter (Rabi et al., International Journal of Pharmaceutical Compounding, 2016. PMID 28339391).
• Amitriptyline — 2% to 5%, a tricyclic with sodium-channel and NMDA-modulating properties. A randomised comparison of topical amitriptyline versus lidocaine in neuropathic pain found both produced modest effects, with neither clearly superior (Ho et al., The Clinical Journal of Pain, 2008. PMID 18180637).
• Gabapentin — commonly 6% to 10%, a calcium-channel modulator. A pilot study of topical amitriptyline, ketamine and a combination in neuropathic pain provided early signal for multi-active formulations (Lynch et al., The Clinical Journal of Pain, 2003. PMID 12966259).
• Lidocaine — 1% to 5%, a sodium-channel blocker. Evidence is strongest for the 5% medicated patch in post-herpetic neuralgia; compounded creams at similar concentrations are used when a patch is unsuitable.
• NSAIDs (e.g. diclofenac, ketoprofen) — 1% to 3%, for localised inflammatory and musculoskeletal pain.
• Capsaicin — 0.025% to 0.075% for regular use, or 8% for clinician-applied single-dose application. A Cochrane review confirmed moderate-quality evidence for high-concentration capsaicin in chronic neuropathic pain (Derry et al., Cochrane Database of Systematic Reviews, 2017. PMID 28085183).

Multi-active formulations combine actives targeting different pain pathways — for example, a sodium-channel blocker, an NMDA antagonist and a calcium-channel modulator in a single base. The rationale is mechanistic; the clinical evidence for specific combinations remains limited and prescribers should set realistic expectations with patients.

Excipients and their roles

Excipients in a compounded pain cream serve specific functions: the base vehicle controls release and penetration, penetration enhancers (such as lecithin in PLO, or propylene glycol) increase flux across the stratum corneum, preservatives prevent microbial growth in aqueous formulations, and pH adjusters maintain the active in its active form. The selection of each excipient must be checked against the patient’s known sensitivities and the compatibility requirements of the chosen actives.

Compounding steps and calculations

The compounding process for a non-sterile topical pain cream follows a defined sequence:

1. Verify the prescription — confirm the patient name, active(s), concentration(s), dosage form, quantity and any excipient exclusions.
2. Calculate the quantity of each active — for example, a 30 g tube of 5% ketamine requires 1.5 g of ketamine base. Calculations should be double-checked and documented.
3. Weigh and measure — using a calibrated balance and appropriate weights and measures. Actives are typically incorporated using geometric dilution to ensure uniform distribution.
4. Prepare the base — the vehicle is prepared or selected, and the active is incorporated by levigation in a mortar and pestle or on a slab, then transferred to the final container.
5. Mix and homogenise — thorough mixing is essential, particularly for multi-active formulations, to avoid concentration hotspots.
6. Label and document — the preparation is labelled with all required information and the compounding record is completed.

Stability and beyond-use dating

Compounded preparations carry a beyond-use date (BUD), not a factory expiry date. The BUD is assigned based on the stability of the active(s) in the chosen base, the water activity of the formulation, and the packaging. Published stability studies provide guidance for common actives:

A study of compounded gabapentin in several commonly used bases determined stability and appropriate BUDs, finding that gabapentin was stable for varying periods depending on the vehicle (Shakshuki et al., Journal of the American Pharmacists Association, 2019. PMID 30979575). A stability-indicating HPLC assay for compounded topical gels containing multiple actives provided a framework for BUD determination in multi-active preparations (Gorman et al., International Journal of Pharmaceutical Compounding, 2017. PMID 28346213). A study of ketoprofen in pluronic lecithin organogel evaluated stability and determined an appropriate BUD for that specific active-base combination (Peacock et al., International Journal of Pharmaceutical Compounding, 2014. PMID 25474865). More recently, a stability evaluation of compounded benzocaine, lidocaine and tetracaine in a cream base demonstrated that these anaesthetics remained stable within defined BUDs (Friciu et al., International Journal of Pharmaceutical Compounding, 2026. PMID 42143784).

Where published stability data are unavailable for a specific active-base combination, a conservative default BUD is applied, and the pharmacy should be able to explain the basis for the assigned date.

Packaging and labelling

Compounded pain creams are typically packaged in metal tubes, plastic tubes or jars, selected for compatibility with the formulation and the quantity dispensed. Labelling must include the patient’s name, the active(s) and concentration(s), the dosage form, the quantity, the BUD, storage instructions, the prescription number, the prescriber’s name, and the pharmacy’s details. Any specific handling instructions — such as “apply thinly to clean, dry skin” or “wash hands after application” — should be included.

Counselling points for clinicians and pharmacists

When a compounded pain cream is dispensed, the following points should be communicated to the patient and documented in the clinical record:

• Application technique — apply a thin layer to clean, dry skin over the painful area; rub in gently. Do not apply to broken skin unless specifically directed.
• Frequency — typically 2 to 4 times daily, as prescribed. Consistent application over 1–2 weeks may be needed before full effect is apparent.
• Hand washing — wash hands thoroughly after application to avoid transfer to eyes or mucous membranes.
• Heat and occlusion — do not apply heat (hot packs, heating pads) to the treated area, as this can increase absorption unpredictably.
• Expected outcome — the goal is typically partial pain reduction (30–70%), not complete elimination. Set this expectation early.
• Adverse effects — local redness, burning or itching may occur; if persistent or severe, the patient should contact the prescriber or pharmacist.

Safety, contraindications and monitoring

Topical analgesics are generally associated with lower systemic side-effect burden than oral therapy, but they are not without risk. Key safety considerations include:

• Allergy or sensitivity — any active or excipient can cause contact dermatitis. A known allergy to an active is an absolute contraindication; excipient sensitivities should be communicated to the compounding pharmacy so alternatives can be selected.
• Pregnancy and lactation — the prescriber must weigh the risk-benefit profile. Some actives (e.g. NSAIDs, ketamine) have specific cautions in pregnancy.
• Application site — avoid application to broken or infected skin unless specifically directed. Mucous membrane application requires a separate formulation decision.
• Systemic absorption — while generally low, systemic absorption increases with large application areas, broken skin, occlusion, or heat. Patients on multiple topical preparations should be monitored for cumulative effects.
• Monitoring — a review at 2–4 weeks is reasonable to assess response. If pain is not reduced, the prescriber may adjust the concentration, change the active combination, or reconsider the diagnosis.

Common compounding pitfalls

• Inadequate mixing — in multi-active formulations, poor homogenisation leads to dose variability within the same tube. Geometric dilution and thorough levigation are essential.
• Base-active incompatibility — some actives are unstable in aqueous bases or at certain pH ranges. The pharmacy should verify compatibility before preparation.
• Unrealistic BUDs — assigning a BUD without reference to stability data can lead to degradation before the preparation is finished. Published stability studies should guide the assigned date.
• Penetration enhancer excess — over-use of penetration enhancers can cause irritation without improving clinical outcome. The concentration should be evidence-based, not arbitrary.
• Inadequate labelling — missing BUD, storage instructions or patient name renders the preparation non-compliant and potentially unsafe.

Discussing a pain cream preparation with Lynnity

Lynnity Pharma, a non-sterile compounding pharmacy in Kuala Lumpur serving the Klang Valley with enquiries also from Singapore, prepares compounded pain creams on a named-patient prescription from a registered doctor, under Good Compounding Practice (GCP). The pharmacy prepares creams as one of its five non-sterile dosage forms (capsule, liquid, cream, tonic, serum), and the existing published guidance on compounded pain cream formulations for diabetic nerve discomfort confirms that multi-active preparations — including gabapentin, lidocaine, ketamine and amitriptyline in a PLO cream base — are within the pharmacy’s compounding scope. Liposomal delivery, confirmed in Lynnity’s published material on topical delivery bases, is an additional vehicle option where the prescriber’s formulation brief calls for enhanced penetration of a lipophilic active.

A clinician wishing to discuss a patient-specific pain cream formulation can send the prescription with a concise formulation brief — the clinical rationale, the anatomical site, any known excipient exclusions, and the desired active(s) and concentration(s) — and the pharmacy will assess compatibility and stability before preparing. This collaborative step is described in the prescriber’s checklist published on lynnitypharma.com.

Medically reviewed by Vitthia Rama Murti, RPh (RPh 15632).

Frequently asked questions

What actives are commonly used in a compounded pain cream?

Common actives include ketamine (1–10%), amitriptyline (2–5%), gabapentin (6–10%), lidocaine (1–5%), NSAIDs such as diclofenac or ketoprofen (1–3%), and capsaicin (0.025–0.075%). Multi-active formulations combine actives targeting different pain pathways — for example, an NMDA antagonist with a sodium-channel blocker and a calcium-channel modulator. The choice depends on the pain mechanism, the patient’s sensitivities, and the prescriber’s clinical judgement.

How is the beyond-use date for a compounded pain cream determined?

The BUD is assigned based on published stability data for the specific active(s) in the chosen base, the water activity of the formulation, and the packaging. Where stability studies exist for the active-base combination, they guide the assigned date. Where they do not, a conservative default is applied. The pharmacy should be able to explain the basis for every BUD it assigns.

What base is most commonly used for compounded pain creams?

Pluronic lecithin organogel (PLO) is widely used because it enhances penetration of lipophilic actives. Other options include anhydrous and aqueous cream bases, selected for compatibility with the specific active and the patient’s excipient tolerances. The base governs release, penetration and tolerability, so it is a clinical as well as a pharmaceutical decision.

What counselling should accompany a compounded pain cream?

Patients should be advised to apply a thin layer to clean, dry skin, wash hands after application, avoid heat and occlusion on the treated area, and expect partial rather than complete pain relief. A review at 2–4 weeks is reasonable to assess response. Local irritation should be reported to the prescriber or pharmacist.

Is a compounded pain cream suitable for all types of pain?

Topical analgesia is most appropriate for localised pain where the source is accessible to transdermal delivery — focal musculoskeletal pain, localised neuropathic pain, and specific inflammatory conditions. It is not suitable for widespread or central pain syndromes where systemic therapy is required. The decision is the prescriber’s clinical judgement, informed by the evidence for each active in the relevant pain type.